[Clinical experience in the diagnosis and therapy of plasmacytoma (author's transl)].
8 patients with plasmocytomas were treated with Endoxan and compared with 5 patients without any considerable treatment. Diagnosis, therapy and prognosis of plasmocytoma are discussed. Particularly mentioned are 3 patients with secondary tumours during cytostatic treatment, a plasmocytoma without paraprotein, a tumorous plasmocytoma with double paraproteinemia and a gammopathia with further development into a plasmocytoma 10 years later.
D000368:Aged; D000477:Alkylating Agents / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006942:Hypergammaglobulinemia / Q000150:complications; D007070:Immunoglobulin A; D007072:Immunoglobulin D; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D010954:Plasmacytoma / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D011379:Prognosis
D000477:Alkylating Agents; D007070:Immunoglobulin A; D007072:Immunoglobulin D; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D003520:Cyclophosphamide; D008558:Melphalan
Klinische Erfahrungen in Diagnostik und Therapie des Plasmozytoms.